Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acrivon Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACRV
Nasdaq
8731
https://acrivon.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acrivon Therapeutics Inc
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- Apr 24th, 2024 8:01 pm
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- Apr 17th, 2024 12:01 am
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Apr 10th, 2024 12:00 pm
Acrivon Therapeutics Announces $130 Million Private Placement Financing
- Apr 9th, 2024 11:00 am
Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ...
- Mar 30th, 2024 9:31 am
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
- Mar 29th, 2024 12:02 pm
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Mar 28th, 2024 12:00 pm
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
- Mar 5th, 2024 9:30 pm
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
- Mar 4th, 2024 1:00 pm
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
- Feb 27th, 2024 1:00 pm
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
- Feb 8th, 2024 1:00 pm
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 1:00 pm
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan 12th, 2024 9:00 pm
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2024 1:00 pm
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
- Jan 3rd, 2024 1:00 pm
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
- Nov 28th, 2023 1:00 pm
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
- Nov 21st, 2023 1:00 pm
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Nov 21st, 2023 1:00 pm
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Nov 9th, 2023 1:01 pm
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 16th, 2023 12:00 pm
Scroll